AXSM

156.08

1.27% 1.96

Dopo l'orario di chiusura: 156.08

Axsome Therapeutics Inc (AXSM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AXSM Giù? Forum Previsione

Precedente Chiudi:

$154.12

Aprire:

$154.55

Volume 24 ore:

854.16K

Relative Volume:

1.31

Capitalizzazione di mercato:

$7.98B

Reddito:

$638.50M

Utile/perdita netta:

$-183.17M

Rapporto P/E:

-42.25

EPS:

-3.6943

Flusso di cassa netto:

$-93.89M

1 W Prestazione:

-3.85%

1M Prestazione:

-13.87%

6M Prestazione:

+31.80%

1 anno Prestazione:

+28.30%

Intervallo 1D:

$153.66

$157.75

Intervallo di 1 settimana:

$153.37

$169.11

Portata 52W:

$86.99

$191.50

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Nome

Axsome Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(212) 332-3241

Indirizzo

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Dipendente

925

Cinguettio

Prossima data di guadagno

2026-02-23

Ultimi documenti SEC

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AXSM Axsome Therapeutics Inc	156.08	7.98B	638.50M	-183.17M	-93.89M	-3.6943
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-01	Iniziato	B. Riley Securities	Buy
2025-09-03	Ripresa	Wells Fargo	Overweight
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-06-03	Iniziato	Oppenheimer	Outperform
2025-04-07	Iniziato	Jefferies	Buy
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-31	Reiterato	Mizuho	Outperform
2024-09-03	Iniziato	Wells Fargo	Overweight
2024-08-06	Aggiornamento	BofA Securities	Neutral → Buy
2024-07-22	Iniziato	Needham	Buy
2024-04-29	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-06	Iniziato	UBS	Buy
2024-01-25	Iniziato	RBC Capital Mkts	Outperform
2023-12-13	Iniziato	Citigroup	Buy
2023-08-08	Aggiornamento	BofA Securities	Underperform → Neutral
2023-01-05	Iniziato	Piper Sandler	Neutral
2022-11-01	Iniziato	Loop Capital	Buy
2022-09-07	Ripresa	Mizuho	Buy
2021-08-10	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Iniziato	Berenberg	Buy
2021-01-08	Iniziato	Jefferies	Buy
2020-12-16	Iniziato	Mizuho	Buy
2020-09-29	Iniziato	BofA Securities	Underperform
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-04-28	Reiterato	H.C. Wainwright	Buy
2020-04-14	Iniziato	Cowen	Outperform
2019-12-30	Reiterato	H.C. Wainwright	Buy
2019-12-17	Reiterato	H.C. Wainwright	Buy
2019-12-16	Reiterato	Guggenheim	Buy
2019-10-16	Iniziato	Guggenheim	Buy
2019-09-18	Iniziato	William Blair	Outperform
2019-05-28	Iniziato	SunTrust	Buy
2019-05-23	Reiterato	H.C. Wainwright	Buy
2019-04-08	Iniziato	SVB Leerink	Outperform
2019-03-15	Reiterato	H.C. Wainwright	Buy
2016-10-03	Ripresa	Brean Capital	Buy
2015-12-15	Iniziato	Cantor Fitzgerald	Buy
2015-12-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

Mar 14, 2026

A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st

Mar 14, 2026

Mar 13, 2026

Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 13, 2026

AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget

Mar 13, 2026

AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView

Mar 13, 2026

RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada

Mar 13, 2026

Mar 12, 2026

Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - Yahoo Finance

Mar 12, 2026

Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st

Mar 12, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Mar 12, 2026

Mar 10, 2026

Axsome Therapeutics at The Citizens Life Sciences Conference: Strategic Growth Plans - Investing.com Canada

Mar 10, 2026

AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView

Mar 10, 2026

AXSM: April 2026 PDUFA for Auvelity in Alzheimer's agitation is a key near-term catalyst - TradingView

Mar 10, 2026

A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Yahoo Finance

Mar 10, 2026

2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail

Mar 10, 2026

Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - MarketBeat

Mar 10, 2026

Inceptionr LLC Invests $1.05 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Mar 10, 2026

Mar 09, 2026

Axsome Therapeutics at Leerink Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Mar 09, 2026

AXSM: Auvelity accelerates growth and pipeline advances with major expansions and new clinical programs - TradingView

Mar 09, 2026

Mar 08, 2026